Why newly-diagnosed lung cancer patients should get this test done before starting treatment

A examination conducted in Virginia revealed that nearly a quarter of all newly-diagnosed patients with advanced lung cancer were not given a test that could improve their chances for long-term survival and reduce the side effects associated with healing More stories What cancer patients families should know about clinical trials in the DC area Close doesn t count Biomarker testing crucial for modern lung cancer recovery On year cancerversary WTOP s Neal Augenstein reflects on living with lung cancer The research company led by Ram Subramanian a thoracic clinical oncologist at the Inova Schar Cancer Institute discovered that nearly one-fourth of U S patients whose initial biopsy revealed cancer did not receive additional biomarker testing to determine whether the individual s cancer contained the epidermal rise factor receptor mutation which is abbreviated as EGFR The importance of testing is if they have that mutation then the remedy is very different and the client outcomes are also much better Subramanian described WTOP s Neal Augenstein A victim with an EGFR mutation can be treated with a one-pill-a-day targeted therapy without needing chemotherapy We all know that chemotherapy is not easy to undergo Subramanian revealed You can give only the targeted therapy so you don t have to come in every three weeks for IV infusion multiple of them are able to function at a near-normal fashion like continue their work and go about their daily routine as they would want to I was diagnosed with stage EGFR-positive lung cancer in November by doctors at Inova Schar After a sparse months of targeted therapy and a lobectomy I ve been cancer-free since May while continuing my one-pill-a-day regimen According to the American Lung Association EGFR-positive lung cancers represent about - of lung cancers in the U S majority of often appearing in the adenocarcinoma subtype of non-small cell lung cancer Patients with lung cancers with EGFR mutations tend to have a minimal to no smoking history but EGFR mutations can appear in patients with other types of lung cancer e g squamous and smoking histories Why it s pivotal to test before starting rehabilitation One of the challenges facing patients and oncologists is the latest biomarker testing called next-generation sequencing or NGS typically can take a sparse weeks to complete Two or three weeks is a lot of time because a sufferer s characteristics can change in that time and just the anxiety of waiting is a lot for the individual Subramanian mentioned In a WTOP interview Stephen Liu director of Thoracic Oncology and Developmental Therapeutics at Georgetown University declared the wait can be taxing on a sufferer It s very common for there to be this urgency to begin therapy which is absolutely understandable Liu noted You get the sense that this cancer has particular momentum and you want to start rehabilitation the day before Subramanian announced it s critical to gather all the information about a person s particular cancer before beginning to treat it If we don t wait for that and we start a different rehabilitation like immunotherapy or immunotherapy plus chemotherapy we know that particular of the patients do worse Subramanian explained So it s key that we get the testing done and then start healing because not only do they do better particular of the side effects and worse outcomes that we could have with a different restoration can also be avoided The length of time the cancer is controlled or even our chance of achieving a cure is significantly improved when they re on the right therapy added Subramanian He s hopeful this assessment will continue to raise awareness of the importance of testing for mutations early In this investigation we were seeing about - of these patients having tests done he announced Particular of the newer material is indicating that testing is coming as high as Source